Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea.

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea. Electrolyte Blood Press. 2018 Dec;16(2):23-26 Authors: Kim HY, Lee SJ, Kim BK, Kim M, Bae EH, Ma SK, Kim SW Abstract A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD. PMID: 30899311 [PubMed]
Source: Electrolyte and Blood Pressure - Category: Internal Medicine Tags: Electrolyte Blood Press Source Type: research